Welcome To Greenwich LifeSciences
Greenwich LifeSciences (Nasdaq: GLSI) is a public clinical-stage biopharmaceutical company focused on the development of an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.

Discover
Greenwich LifeSciences’ lead product is GP2, an immunotherapy derived from the HER2/neu protein that is expressed in breast cancer and many other common cancers.

Multiple Studies Have Shown Both Safety and Efficacy
Statistically significant Phase IIb clinical trial data shows that after median 5 years of follow-up, HER2/neu positive breast cancer patients treated with the GP2 immunotherapy had:

No cancer recurrences if treated, followed, and remained disease-free over the first 6 months
Peak immunity at 6 months
No serious adverse events attributable to treatment
A well tolerated safety profile
Greenwich LifeSciences has commenced a Phase III clinical trial, Flamingo-01, that is conservatively designed to reproduce the Phase IIb clinical trial results and to continue to save lives.

For the 146 patients who have been treated with GP2 immunotherapy to date over 4 clinical trials, treatment was well tolerated and no serious adverse events were observed related to the immunotherapy.

Greenwich LifeSciences, Inc. Downloads

Contact supplier